Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Kent Y. Feng, MD; Rahul S. Loungani, MD; Vishal N. Rao, MD, MPH; Chetan B. Patel, MD; Michel G. Khouri, MD; G. Michael Felker, MD, MHS; Adam D. DeVore, MD, MHS

JACC. CardioOncology (Dec 2019)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Kent Y. Feng, MD,
Rahul S. Loungani, MD,
Vishal N. Rao, MD, MPH,
Chetan B. Patel, MD,
Michel G. Khouri, MD,
G. Michael Felker, MD, MHS,
Adam D. DeVore, MD, MHS

Affiliations

Kent Y. Feng, MD: Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California
Rahul S. Loungani, MD: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
Vishal N. Rao, MD, MPH: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
Chetan B. Patel, MD: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina
Michel G. Khouri, MD: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina
G. Michael Felker, MD, MHS: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina
Adam D. DeVore, MD, MHS: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina; Address for correspondence: Dr. Adam D. DeVore, Duke Clinical Research Institute, 200 Morris Street, #6318, Durham, North Carolina 27701.

Journal volume & issue: Vol. 1, no. 2
pp. 273 – 279

Abstract

Read online

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.

Published in JACC. CardioOncology

ISSN: 2666-0873 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jacc-cardiooncology

About the journal

Abstract

Keywords